What Has Been the Progress and Growth of the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market in Recent Years?
The hereditary breast and ovarian cancer syndrome treatment market has seen considerable growth due to a variety of factors.
• The market size for treating hereditary breast and ovarian cancer syndrome has experienced significant growth recently. It is projected to expand from $6.72 billion in 2024 to $7.17 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.6%.
The notable growth during the historical period can be attributed to several factors: heightened awareness and screening initiatives, government support policies, patient advocacy and empowerment, and collaborative research efforts.
How Does the Forecast Look for the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The hereditary breast and ovarian cancer syndrome treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for the treatment of hereditary breast and ovarian cancer syndrome is predicted to experience significant growth in the coming years. It is projected to reach $9.19 billion in 2029, displaying a compound annual growth rate (CAGR) of 6.4%.
This projected growth during the forecast period can be credited to the increased influence of artificial intelligence, broader access to genetic counseling, approvals from regulatory bodies for targeted therapies, personalized treatment schemes, and global partnerships in research. Key trends for the forecast period involve gene editing technologies, advancements in immunotherapy, technological innovation in oncology, immunotherapy tailored for BRCA-related cancers, and comprehensive multidisciplinary care.
What Are The Leading Drivers Of Growth In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The escalating prevalence of genetic disorders is anticipated to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market. All newborns are immediately screened after birth for specific health issues, a practice used by health professionals to detect and address certain needs before the newborn gets ill. This method could help pinpoint babies with a high risk of developing breast and ovarian cancer, enabling early commencement of preventive measures. For example, data from the Texas Department of State Health Services in 2022 showed a 4.3% increase in total specimens received for newborn screening from 729,347 in 2021 to 761,000 in 2022. Moreover, about 394,000 babies were screened, and when the year ended, 1,130 babies had one of the NBS disorders. Consequently, this surge in genetic disorders propels the growth of the hereditary breast and ovarian cancer syndrome treatment market. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Driver: Surging Incidence Of Ovarian Cancer Fuels Growth In The Hereditary Breast And Ovarian Cancer Syndrome Treatment Market
How Are The Segments Defined Within The Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The hereditary breast and ovarian cancer syndrome treatment market covered in this report is segmented –
1) By Treatment: Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments
2) By Diagnosis: Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
2) By Chemoprevention: Tamoxifen, Raloxifene
3) By Genetic Counselling: Risk Assessment, Family Planning Guidance
4) By Medication: Targeted Therapies, Immune Checkpoint Inhibitors
5) By Other Treatments: Preventive Surgery, Surveillance Strategies
Pre-Book The Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Leading companies in the hereditary breast and ovarian cancer syndrome treatment market are implementing innovative treatment methods, including comprehensive risk assessments, to offer dependable services to their clients. This in-depth risk evaluation is a tool designed to gauge a person's probability of developing a particular disorder or exhibiting a disease symptom. For example, in February 2023, an established molecular diagnostics firm from Australia, Genetic Technologies Limited, introduced a revolutionary comprehensive risk evaluation test meant for treating breast and ovarian cancer. This test integrates gene mutation testing for breast and ovarian cancers, hereditary and non-hereditary risk components, along with the GeneType risk score for both cancers. Its distinctive approach amalgamates the identification of the 13 foremost actionable genes linked to breast and ovarian cancer susceptibility in conjunction with the GeneType test platform. This advanced test platform is aimed at women over 30 who, barring unusual genetic modifications, are potentially at a higher risk of developing breast and ovarian cancer within the general population.
Who Are the Key Players In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are:
• Pfizer Inc.
• Johnson & Johnson Private Limited
• F. Hoffmann-La Roche Ltd.
• Merck & Co.
• AbbVie Inc.
• Bayer AG
• Sanofi-Aventis LLC
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Co. Ltd.
• Vertex Pharmaceuticals Inc.
• Mercy Health
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Lupin Limited
• Seagen Inc.
• LEO Pharma Inc.
• LifeLabs Genetics
• Natera Inc.
• Fresenius Kabi AG
• Myriad Genetics Inc.
• Invitae Corporation
• Editas Medicine Inc.
• GenMark Diagnostics Inc.
• Genentech Inc.
• CRISPR Therapeutics AG
• Advocate Health Care
What Is The Most Dominant Region In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
